{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T08:01:10Z","timestamp":1794470470207,"version":"4.9.1"},"reference-count":38,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100003517","name":"Wipe Out Kids\u2019 Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003517","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018138","name":"Kuni Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018138","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sam Day Foundation"},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000937","name":"M.J. Murdock Charitable Trust","doi-asserted-by":"publisher","award":["SR-20221337"],"award-info":[{"award-number":["SR-20221337"]}],"id":[{"id":"10.13039\/100000937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Metastatic and relapsed osteosarcoma remains difficult to treat despite advanced surgical techniques, intensified chemotherapy, and targeted therapies. Adoptive immunotherapies such as chimeric antigen receptor (CAR) T cells are in their nascent stage but remain a viable therapeutic strategy for patients with aggressive solid tumors such as osteosarcoma. Folate receptor-\u03b1 (FOLR1) has been functionally implicated in osteosarcoma pathophysiology, providing rationale as a potential therapeutic target. We recently advanced a FOLR1-specific CAR T-cell product (FH FOLR1-CART) into a trial in infant acute myeloid leukemia (NCT06609928) and now evaluate this CAR construct against osteosarcoma. We provide comprehensive FOLR1 transcript and protein expression profile in patients with osteosarcoma, cell lines, and patient-derived xenografts, substantiating its significance as a therapeutic target. We further evaluate the in vitro and in vivo efficacy of FH FOLR1-CART in both standard and patient-derived osteosarcoma cell lines and xenograft models. FOLR1 transcript is expressed in the overwhelming majority of osteosarcoma primary patient specimens, osteosarcoma cell lines, and patient-derived models. FH FOLR1-CART exhibits robust in vitro activation and potent cytotoxicity against FOLR1-expressing osteosarcoma cell lines and primary osteosarcoma patient samples. More importantly, FH FOLR1-CART demonstrates potent antitumor activity in both localized and metastatic in vivo cell-derived and patient-derived xenograft models, with complete tumor eradication. These results demonstrate a potential therapeutic option for patients with advanced osteosarcoma. FH FOLR1-CART is advancing to an early-phase trial in relapsed\/refractory osteosarcoma at Fred Hutchinson Cancer Center and Seattle Children\u2019s Hospital.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>FOLR1 expression has previously been implicated in the pathogenesis of treatment-resistant osteosarcoma. This report demonstrates FOLR1 expression by most osteosarcoma tumors and provides preclinical evidence of robust antitumor activity both in vitro and in vivo against xenograft osteosarcoma models exhibited by FH FOLR1-CART. These data support ongoing efforts for clinical translation of FH FOLR1-CART to an early-phase clinical trial for patients with aggressive osteosarcoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0086","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T12:58:50Z","timestamp":1757336330000},"page":"1701-1713","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Preclinical Evaluation of Folate Receptor-\u03b1 Chimeric Antigen Receptor T Cells Exhibits Highly Efficient Antitumor Activity against Osteosarcoma"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9850-9435","authenticated-orcid":false,"given":"Michelle","family":"Choe","sequence":"first","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."},{"name":"2Cancer and Blood Disorder Center, Seattle Children\u2019s Hospital, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-9416","authenticated-orcid":false,"given":"Danielle","family":"Kirkey","sequence":"additional","affiliation":[{"name":"2Cancer and Blood Disorder Center, Seattle Children\u2019s Hospital, Seattle, Washington."},{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1514-2102","authenticated-orcid":false,"given":"Isabel","family":"Lira","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6253-078X","authenticated-orcid":false,"given":"Grace","family":"Hawkins","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9762-7152","authenticated-orcid":false,"given":"Melia","family":"Blankenfeld","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6016-2592","authenticated-orcid":false,"given":"Sarah","family":"Menashe","sequence":"additional","affiliation":[{"name":"4Department of Radiology, Seattle Children\u2019s Hospital, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-7923","authenticated-orcid":false,"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6337-2198","authenticated-orcid":false,"given":"Brianna","family":"Wrightson","sequence":"additional","affiliation":[{"name":"5Preclinical Imaging Shared Resources, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9145-3516","authenticated-orcid":false,"given":"Christina","family":"Root","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5124-5750","authenticated-orcid":false,"given":"Cyd N.","family":"McKay","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5097-0652","authenticated-orcid":false,"given":"Jack H.","family":"Peplinski","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-8830","authenticated-orcid":false,"given":"Raisa","family":"Glabman","sequence":"additional","affiliation":[{"name":"6Comparative Pathology, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-1611","authenticated-orcid":false,"given":"Lara E.","family":"Davis","sequence":"additional","affiliation":[{"name":"7Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4056-5033","authenticated-orcid":false,"given":"Sanjay V.","family":"Malhotra","sequence":"additional","affiliation":[{"name":"7Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon."},{"name":"8Department of Cell, Developmental and Cancer Biology, Oregon Health & Science University, Portland, Oregon."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8995-2929","authenticated-orcid":false,"given":"Richard","family":"Gorlick","sequence":"additional","affiliation":[{"name":"9Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3432-0443","authenticated-orcid":false,"given":"Elizabeth T.","family":"Loggers","sequence":"additional","affiliation":[{"name":"1Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-4423","authenticated-orcid":false,"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"3Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"key":"2025092303130356800_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2217\/fon-2016-0261","article-title":"Novel insights and therapeutic interventions for pediatric osteosarcoma","volume":"13","author":"Kager","year":"2017","journal-title":"Future Oncol"},{"key":"2025092303130356800_bib2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1200\/JCO.2005.04.063","article-title":"Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)","volume":"23","author":"Kempf-Bielack","year":"2005","journal-title":"J Clin Oncol"},{"key":"2025092303130356800_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.2008.16.2305","article-title":"Second and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patients","volume":"27","author":"Bielack","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025092303130356800_bib4","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 6","key":"2025092303130356800_bib5","doi-asserted-by":"crossref","first-page":"e30583","DOI":"10.1002\/pbc.30583","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: bone tumors","volume":"70","author":"Reed","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"2025092303130356800_bib6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","article-title":"GD2-CART01 for relapsed or refractory high-risk neuroblastoma","volume":"388","author":"Del Bufalo","year":"2023","journal-title":"New Engl J Med"},{"key":"2025092303130356800_bib7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"2025092303130356800_bib8","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1200\/JCO.23.02229","article-title":"STRIvE-02: a first-in-human phase I study of systemically administered B7-H3 chimeric antigen receptor T cells for patients with relapsed\/refractory solid tumors","volume":"42","author":"Pinto","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025092303130356800_bib9","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","article-title":"Interleukin-15-armored GPC3-CAR T cells for patients with solid cancers","volume":"637","author":"Steffin","year":"2025","journal-title":"Nature"},{"key":"2025092303130356800_bib10","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet"},{"key":"2025092303130356800_bib11","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","article-title":"Exploiting the folate receptor \u03b1 in oncology","volume":"17","author":"Scaranti","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"2025092303130356800_bib12","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.addr.2004.01.001","article-title":"Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy","volume":"56","author":"Elnakat","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"2025092303130356800_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tem.2021.12.003","article-title":"Emerging roles for folate receptor FOLR1 in signaling and cancer","volume":"33","author":"Nawaz","year":"2022","journal-title":"Trends Endocrinol Metab"},{"key":"2025092303130356800_bib14","doi-asserted-by":"crossref","first-page":"52553","DOI":"10.18632\/oncotarget.9651","article-title":"Targeting folate receptor alpha for cancer treatment","volume":"7","author":"Cheung","year":"2016","journal-title":"Oncotarget"},{"key":"2025092303130356800_bib15","first-page":"e61032","article-title":"Expression of the folate receptor proteins FOLR1 and FOLR2 in correlation with clinicopathological variables of gastric cancer","volume":"16","author":"Anitha","year":"2024","journal-title":"Cureus"},{"key":"2025092303130356800_bib16","doi-asserted-by":"crossref","first-page":"15330338221141795","DOI":"10.1177\/15330338221141795","article-title":"High expression of folate receptor alpha (FOLR1) is associated with aggressive tumor behavior, poor response to chemoradiotherapy, and worse survival in rectal cancer","volume":"21","author":"Chen","year":"2022","journal-title":"Technol Cancer Res Treat"},{"key":"2025092303130356800_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/1354750X.2020.1771420","article-title":"A systematic review and meta-analysis of higher expression of folate receptor alpha (FOLR1) predicts poor cancer prognosis","volume":"25","author":"Liu","year":"2020","journal-title":"Biomarkers"},{"key":"2025092303130356800_bib18","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1158\/1078-0432.CCR-06-1343","article-title":"The folate receptor \u03b1 is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate","volume":"13","author":"Yang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2025092303130356800_bib19","doi-asserted-by":"crossref","first-page":"e184305","DOI":"10.1172\/JCI184305","article-title":"CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target","volume":"134","author":"Le","year":"2024","journal-title":"J Clin Invest"},{"key":"2025092303130356800_bib20","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/1078-0432.CCR-19-1800","article-title":"Comprehensive transcriptome profiling of cryptic CBFA2T3-GLIS2 fusion-positive AML defines novel therapeutic options: a COG and TARGET pediatric AML study","volume":"26","author":"Smith","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025092303130356800_bib21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1158\/2159-8290.CD-20-1230","article-title":"St. Jude Cloud: a pediatric cancer genomic data-sharing ecosystem","volume":"11","author":"McLeod","year":"2021","journal-title":"Cancer Discov"},{"key":"2025092303130356800_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2025092303130356800_bib23","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1158\/0008-5472.CAN-23-0816","article-title":"Analysis and visualization of longitudinal genomic and clinical data from the AACR project GENIE Biopharma Collaborative in cBioPortal","volume":"83","author":"de Bruijn","year":"2023","journal-title":"Cancer Res"},{"key":"2025092303130356800_bib24","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2025092303130356800_bib25","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025092303130356800_bib26","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1200\/JCO.2003.08.132","article-title":"Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols","volume":"21","author":"Kager","year":"2003","journal-title":"J Clin Oncol"},{"key":"2025092303130356800_bib27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2025092303130356800_bib28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/ijms25021046","article-title":"Folate receptor alpha-a novel approach to cancer therapy","volume":"25","author":"Gonzalez","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2025092303130356800_bib29","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41576-020-0258-4","article-title":"mRNAs, proteins and the emerging principles of gene expression control","volume":"21","author":"Buccitelli","year":"2020","journal-title":"Nat Rev Genet"},{"key":"2025092303130356800_bib30","first-page":"6","article-title":"Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha","volume":"7","author":"Ebel","year":"2007","journal-title":"Cancer Immun"},{"key":"2025092303130356800_bib31","first-page":"e73503","article-title":"Efficacy and safety of farletuzumab in ovarian cancer: a systematic review and single-arm meta-analysis","volume":"16","author":"Fayoud","year":"2024","journal-title":"Cureus"},{"key":"2025092303130356800_bib32","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.4161\/cbt.26106","article-title":"The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity","volume":"14","author":"Lin","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"2025092303130356800_bib33","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1158\/1078-0432.CCR-10-0700","article-title":"Farletuzumab, a humanized monoclonal antibody against folate receptor \u03b1, in epithelial ovarian cancer: a phase I study","volume":"16","author":"Konner","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2025092303130356800_bib34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10637-014-0180-8","article-title":"A phase I study of farletuzumab, a humanized anti-folate receptor \u03b1 monoclonal antibody, in patients with solid tumors","volume":"33","author":"Sasaki","year":"2015","journal-title":"Invest New Drugs"},{"key":"2025092303130356800_bib35","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025092303130356800_bib36","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) \u2013specific chimeric antigen receptor\u2013modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025092303130356800_bib37","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"2025092303130356800_bib38","doi-asserted-by":"crossref","first-page":"167159","DOI":"10.1016\/j.bbadis.2024.167159","article-title":"Armed with IL-2 based fusion protein improves CAR-T cell fitness and efficacy against solid tumors","volume":"1870","author":"Li","year":"2024","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0086\/3648569\/crc-25-0086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1701\/3653614\/crc-25-0086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/9\/1701\/3653614\/crc-25-0086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T07:13:21Z","timestamp":1758611601000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/9\/1701\/765867\/Preclinical-Evaluation-of-Folate-Receptor-Chimeric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0086","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30186179","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186167","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186176","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186188","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186191","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186182","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186194","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186185","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186197","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186173","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30186170","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8049566","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}